Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. BHST
BHST logo

BHST Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy BioHarvest Sciences Inc (BHST) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
3.200
1 Day change
3.56%
52 Week Range
12.800
Analysis Updated At
2026/06/05
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

BHST is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The available data does not provide a reliable bullish setup: there is no technical trend data, no option sentiment, no valuation data, no recent congress trading activity, and no clear proprietary buy signal. With no strong confirmation from the provided inputs, the best decision is to hold off rather than buy immediately.

Technical Analysis

No stock trend data was successfully fetched, so a direct technical trend assessment cannot be confirmed. Based on the limited market information provided, there is no evidence of a strong uptrend, breakout, or momentum signal. The absence of AI Stock Picker and SwingMax signals also means there is no proprietary timing advantage suggesting an immediate entry.

Positive Catalysts

  • No clear positive catalysts were provided in the data. There are no listed bullish news events, no recent insider or politician buying activity, no congress trading support, and no proprietary buy signal today.

Neutral/Negative Catalysts

  • No valuation data is available, stock trend data could not be fetched, and there is no recent congress trading activity. The lack of AI Stock Picker and SwingMax signals reduces confidence in near-term upside timing.

Financial Performance

No financial data was provided, so the latest quarter financial performance and growth trends cannot be assessed.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no visible recent Wall Street pros and cons view to summarize.

Wall Street analysts forecast BHST stock price to rise
3 Analyst Rating
Wall Street analysts forecast BHST stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.090
sliders
Low
12
Averages
13
High
14
Current: 3.090
sliders
Low
12
Averages
13
High
14
Roth Capital
Sean McGowan
Buy
initiated
$10
AI Analysis
2026-02-19
Reason
Roth Capital
Sean McGowan
Price Target
$10
AI Analysis
2026-02-19
initiated
Buy
Reason
Roth Capital analyst Sean McGowan initiated coverage of BioHarvest Sciences with a Buy rating and $10 price target. The firm believes the company's botanical synthesis platform will drive "significant" revenue growth in the coming years. BioHarvest's annual cash flow should turn sustainably positive beginning in 2027, the analyst tells investors in a research note. Roth cites the company's "rapid growth, expanding footprint and emerging profitability" for the Buy rating.

People Also Watch